PDGFRB and neoplasm of thorax: In phase I/II trials, nivolumab plus vorolanib, an oral VEGFR/PDGFR kinase inhibitor, is in progress for the aim of safety and ORR in 177 patients with pretreated thoracic tumors, including TC (NCT03583086).